Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
The invention provides α-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
1. A kit comprising a compound represented by formula (III)
and a package insert, wherein said package insert instructs a user of said kit to administer said compound to a human subject to treat or prevent preterm labor in said human subject.
2. The kit of claim 1 , wherein said human subject is characterized by a gestational age of from about 24 to about 34 weeks.
3. The kit of claim 1 , wherein said compound is formulated for oral administration to said human subject.
4. The kit of claim 1 , wherein said compound is formulated for intravenous administration to said human subject.
5. The kit of claim 1 , wherein said compound is present within a pharmaceutical composition that further comprises one or more pharmaceutically acceptable excipients.
6. The kit of claim 5 , wherein said pharmaceutical composition is a tablet, capsule, gel cap, powder, liquid solution, or liquid suspension.
7. The kit of claim 1 , wherein said compound is in a crystalline state.
8. The kit of claim 7 , wherein said compound exhibits characteristic X-ray powder diffraction peaks at about 7.0° 2θ, about 8.1° 2θ, about 10.0° 2θ, about 12.0° 2θ, about 13.1° 2θ, about 14.1° 2θ, about 16.4° 2θ, about 18.4° 2θ, about 20.1° 2θ, about 21.0° 2θ, about 23.5° 2θ, and about 29.5° 2θ.
9. The kit of claim 8 , wherein said compound is characterized by an X-ray powder diffraction spectrum substantially as depicted in FIG. 49 .
10. The kit of claim 7 , wherein said compound exhibits 1 H nuclear magnetic resonance (NMR) peaks centered at about 1.1 ppm, about 3.3 ppm, about 4.9 ppm, about 5.4 ppm, about 7.1 ppm, about 7.7 ppm, about 7.9 ppm, and about 8.0 ppm.
11. The kit of claim 10 , wherein said compound is characterized by a 1 H NMR spectrum substantially as depicted in FIG. 21 .
12. The kit of claim 7 , wherein said compound exhibits an endotherm at from about 145° C. to about 147° C. as measured by differential scanning calorimetry.
13. The kit of claim 12 , wherein said compound is characterized by a differential scanning calorimetry curve substantially as depicted in FIG. 20 or FIG. 23 .
14. The kit of claim 7 , wherein said compound exhibits a weight loss of from about 0.2% to about 0.6% when heated from 25° C. to 100° C. as measured by thermogravimetric analysis.
15. The kit of claim 14 , wherein said compound exhibits a thermogravimetric analysis curve substantially as depicted in FIG. 24 .